Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.

Paul ThoueilleSusana Alves SaldanhaVincent DesfontaineKatharina Kusejko Perrine CourletPascal AndreMatthias Cavassini Laurent Arthur Decosterd Thierry Buclin Monia Guidinull null

Published in: The Journal of antimicrobial chemotherapy (2023)

Kidney function markedly affects circulating tenofovir exposure after tenofovir alafenamide administration in PLWH. However, considering its rapid uptake into target cells, we suggest only a cautious increase of tenofovir alafenamide dosage intervals to 2 or 3 days only in case of moderate or severe CKD, respectively.

Keyphrases

chronic kidney disease
antiretroviral therapy
induced apoptosis
cell proliferation
oxidative stress
endoplasmic reticulum stress
signaling pathway
pi k akt